BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.
|
|
- Hubert Higgins
- 6 years ago
- Views:
Transcription
1 BRIEF ANTIDEPRESSANT OVERVIEW Casey Gallimore, Pharm.D., M.S.
2 Antidepressant Medication Classes First Generation Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Second Generation Selective Serotonin Reuptake Inhibitors (SSRIs) Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs) Other
3 First Generation Antidepressants
4 Tricyclic Antidepressants (TCAs) Tertiary Amines Imipramine (Tofranil ) Amitriptyline (Elavil ) Demethylated Secondary Amines Desipramine (Norpramin ) Nortriptyline (Pamelor ) Clomipramine (Anafranil ) Doxepin (Silenor )
5 Mechanism of Action: TCAs Inhibits membrane pump mechanism responsible for the absorption of serotonin (5-HT) and norepinephrine (NE) in serotonergic and adrenergic neurons Block muscarinic M1, histamine H1, and alphaadrenergic receptors Amount of 5-HT and NE effects depends on the compound: Tertiary amines = 5-HT > NE reuptake inhibition Secondary amines = NE > 5-HT reuptake inhibition
6 TCA Adverse Effects Block muscarinic M1, histamine H1, and alpha-adrenergic receptors Cardiovascular arrhythmias, tachycardia, orthostatic hypotension Anticholinergic Sedation Neurologic Effects Weight Gain Dangerous in overdose!!! As Sexual Dysfunction little as 10 times the daily dose can be fatal.
7 Responsible receptors Tertiary Amines Muscarinic Histamine Alphaadrenergic Anticholinergic Drowsiness Weight Gain Hypotension QT prolongation 5-HT2 Sexual Dysfunction Amitriptyline Clomipramine Doxepin Imipramine Triimipramine Secondary Amines Desipramine Nortriptyline Protriptyline Miscellaneous Amoxapine Maprotiline high risk, + moderate risk Adapted from UpToDate : Side Effects of Antidepressants (table)
8 Monoamine Oxidase Inhibitors (MAOIs) Phenelzine (Nardil ) Tranylcypromine (Parnate ) Selegiline (Emsam ) Mechanism of Action Irreversible inhibition of MAO-A & B, resulting in increased levels of 5HT, NE, and dopamine Phenelzine and tranylcypromine are non-selective inhibitors Selegiline inhibits MAO-A & B in the brain but has reduced effects in the gut (dose dependent)
9 MAOI Drug Interactions Inhibited metabolism of various monoamines including 5-HT, NE and tyramine can result in: Serotonin syndrome Concurrent serotonergic medications Hypertensive crisis Ingesting large amounts of tyramine or other vasoactive amines in foods or medications Clinical presentation acute onset of severe headache, nausea, neck stiffness, palpitations, profuse perspiration, and confusion can possibly lead to stroke and death
10 MAOI Drug Interactions Concomitant use contraindicated*: Other antidepressants Buspirone Dextromethorphan Sympathomimetic drugs (amphetamine, cocaine, methylphenidate, epinephrine, phenylephrine, etc) Start SSRI or other antidepressant 14 days after stopping MAOI 5 half life wash out of previous antidepressant before starting MAOI * This does not represent a comprehensive list of contraindications
11 MAOI Food Interactions (Tyramine Containing) Absolute Contraindications Aged cheeses, aged and cured meats, banana peel, sauerkraut, soy sauce, tap beer, marmite Moderate Contraindications red or white wine, bottled or canned beer Unnecessary avocados, bananas, chocolate, fresh and mild cheeses, fresh meat, MSG, peanuts, raspberries, soy milk
12 Second Generation Antidepressants
13 Selective Serotonin Reuptake Inhibitors (SSRIs) Citalopram (Celexa ) Escitalopram (Lexapro ) Fluoxetine (Prozac, Prozac Weekly, Sarafem ) Fluvoxamine (Luvox CR) Paroxetine (Paxil, Paxil CR ) Sertraline (Zoloft ) Vilazodone (Viibryd ) Vortioxetine (Trintellix )
14 Mechanism of Action: SSRIs Decreases the action of the presynaptic 5-HT reuptake pump which increases duration of 5-HT in the synapse and increases postsynaptic 5-HT receptor occupancy In addition, vilazodone is 5-HT 1A receptor partial agonist vortioxetine is 5-HT 1A agonist, 5-HT 1B partial agonist, and antagonist of 5-HT 3, 5-HT 1D and 5-HT 7 receptors
15 Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) Venlafaxine (Effexor, Effexor XR ) Desvenlafaxine (Pristiq ) Duloxetine (Cymbalta ) Levomilnacipran (Fetzima ) Selectively inhibit neuronal reuptake of 5-HT and NE
16 SNRIs Venlafaxine predominately 5-HT effects until dose reaches mg per day Desvenlafaxine O-desmethyl metabolite of venlafaxine via CYP2D6 Duloxetine dual 5-HT and NE action along entire dosing spectrum Also FDA approved for diabetic peripheral neuropathy, fibromyalgia, chronic musculoskeletal pain Levomilnacipran greatest noradrenergic activity in vitro among available SNRIs
17 Norephinephrine Dopamine Reuptake Inhibitors (NDRIs) Bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL ) Inhibits neuronal uptake of NE and dopamine Also FDA indication for smoking cessation (Zyban )
18 Other serotonin modulators Mirtazapine (Remeron ) Increases 5-HT and NE release by central presynaptic alpha2- adrenergic antagonist effects Potent antagonist of 5-HT2 and 5-HT3 serotonin receptors and H1 histamine receptors and a moderate peripheral alpha1-adrenergic and muscarinic antagonist Trazodone (Oleptro ) Increases serotonergic neurotransmission Blocks histamine (H1) and alpha1-adrenergic receptors Nefazodone (Serzone ) Antagonist of 5HT-2 receptors and 5-HT reuptake blocking
19 St. John s Wort Herbal product (Hypericum perforatum) Modulates neurotransmitter levels of 5-HT, NE, and dopamine most likely by inhibiting reuptake
20 Shared Adverse Effects Acute GI effects (upset, nausea, vomiting) Dizziness Headache Sedation / Insomnia Anxiety / jitteriness ** usually tolerate out after 1-4 weeks Chronic Sweating Tremor Vivid dreams Increased bleeding risk Hyponatremia Sexual dysfunction Worsening mood / suicide Serotonin syndrome
21 Fluoxetine Sertraline Citalopram & Escitalopram Fluvoxamine Paroxetine Vilazodone (Viibryd) Vortioxetine (Brintellix) -Longest t ½ (self-tapering) -CYP 2D6, 3A4, 2C inhibitor -Diarrhea as adverse effect -Risk of QT prolongation -Few drug-drug interactions -CYP 1A2, 3A4, 2C inhibitor -Often prescribed for OCD -Anticholinergic effects, most sedating, wt gain -Shortest t ½ (withdrawal) -CYP 2D6 inhibitor -SSRI + 5-HT1A receptor partial agonist -Lower risk of sexual dysfunction -SSRI + 5-HT1A agonist, 5-HT1B partial agonist, and antagonist of 5-HT3, 5-HT1D and 5-HT7 receptors -Main ADEs: GI related (nausea, vomiting, constipation)
22 Unique Attributes SNRIs Increased BP and HR (least potential with duloxetine, greatest with venlafaxine) GI effects (upset, N/V, constipation) slow taper, use venlafaxine XR formulation Levomilnacipran (Fetzima ) newest SNRI Bupropion Decreased appetite Restlessness, insomnia (dose earlier in day) Lowered seizure threshold (contraindicated with seizure disorder and eating disorders) Lower risk of sexual dysfunction
23 Unique Attributes Mirtazapine Weight gain Sedation More prominent at lower doses Dry mouth Constipation Lower risk of sexual dysfunction Trazodone Sedation Hypotension Priapism Low incidence of sexual side effects Nefazodone Hepatitis, liver failure 1 per 250,000 to 300,000 patient-years in US Lower risk of sexual dysfunction
24 Place in Therapy
25 First vs Second Generation Antidepressants Equivalent efficacy in treating depression and many anxiety disorders However, second generation agents generally preferred over first generation agents Fewer drug interactions Improved tolerability Greater safety profile
26 FDA-Labeled Indications Antidepressant MDD GAD SAD PD OCD PTSD BPD Citalopram X Escitalopram X X Fluoxetine X X X X Fluvoxamine X Paroxetine X X X X X X Sertraline X X X X X Vilazodone X Vortioxetine X Venlafaxine X X X X Desvenlafaxine X Duloxetine X X Levomilnacipran X Mirtazapine X Trazodone X Nefazodone X Bupropion X MDD=major depressive disorder, GAD=generalized anxiety disorder; SAD=social anxiety disorder, PD=panic disorder, OCD=obsessive compulsive disorder, PTSD=post traumatic stress disorder, BPD=bipolar disorder
27 Thank you for your attention! If you have any questions regarding this presentation feel free to me at
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More information90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR
Pre - PA Allowance 12 years of age or older Quantity Immediate-release Formulation Ultracet 720 dosage units per 90 days OR Ultram 720 dosage units per 90 days Extended-release Formulations Ultram ER 90
More informationOXYCODONE IR (oxycodone)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Oxycodone hydrochloride, a pure opioid agonist, is used in the treatment of moderate to severe pain (1-2). The precise mechanism of action is unknown; however,
More informationBELBUCA (buprenorphine buccal film)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Belbuca is indicated for the management of chronic pain severe enough to require daily, aroundthe-clock, long-acting opioid treatment for which alternative
More informationDuragesic Patch (fentanyl patch) Prior authorization is not required if prescribed by an oncologist
Pre - PA Allowance Quantity 30 patches every 90 days Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist Age 2 years of age or older Diagnosis Patient must have
More informationXartemis XR (oxycodone / acetaminophen extended release)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Xartemis XR is a combination of oxycodone and acetaminophen in a dosage formulation to deliver both immediate pain relief, in less than an hour, and extended-release
More informationHYSINGLA ER (hydrocodone bitartrate) Prior authorization is not required if prescribed by an oncologist.
Pre - PA Allowance None Prior authorization is not required if prescribed by an oncologist. Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: 1. Pain,
More informationMORPHINE IR DRUG CLASS Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone)
Pre - PA Allowance Tablets & Suppositories Morphine sulfate tablets Morphine sulfate suppositories Oxymorphone tablets Hydromorphone tablets Hydromorphone suppositories 360 tablets per 90 days OR 360 suppositories
More informationPre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None
Pre - PA Allowance None Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist and/or the member has paid pharmacy claims for an oncology medication(s) in the past
More informationRATIONALE FOR INCLUSION IN PA PROGRAM
RATIONALE FOR INCLUSION IN PA PROGRAM Background Tramadol is a centrally acting synthetic opioid analgesic used to treat moderate to moderately severe chronic pain in adults. Along from analgesia, tramadol
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationTreating Depression in Adults
Treating Depression in Adults By Deborah Christensen, Ph.D., M.S.C.P. Depressive Disorders represent a broad and heterogeneous group of commonly diagnosed psychological disorders. The DSM adequately describes
More informationCommon Antidepressant Medications for Adults
(and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10
More informationPrimary Care Management of Depression. John Briles, MD, Medical Director October 11, 2017
John Briles, MD, Medical Director October 11, 2017 Molina Healthcare of Michigan uses a HEDIS measure for Antidepressant Medication Management (AMM) to measure how well treating providers (PCPs) appropriately
More informationAnti-Depressant Medications
Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change
More informationPsychobiology Handout
Nsg 85A / Psychiatric Page 1 of 7 Psychobiology Handout STRUCTURE AND FUNCTION OF THE BRAIN Psychiatric illness and the treatment of psychiatric illness alter brain functioning. Some examples of this are
More informationRATIONALE FOR INCLUSION IN PA PROGRAM
RATIONALE FOR INCLUSION IN PA PROGRAM Background hydromorphone (Exalgo, Dilaudid) and oxymorphone (Opana and Opana ER) are Schedule II narcotics prescribed to treat moderate to severe pain. Morphine produces
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationTreatment of Major Depressive Disorder
Treatment of Major Depressive Disorder Sarah Mullowney, MD PGY3 Psychiatry Resident, University of Utah Paula Gibbs, MD Medical Director of 5 West at UUMC Clerkship Director MS III Psychiatric Rotation
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More information3. Atypical antidepressants
3. Atypical antidepressants Bupropion, mirtazapine, nefazodone & trazodone. Mixed group that act at several different sites. Bupropion Acts as a weak dopamine & NE reuptake inhibitor. Has short half-life.
More informationLinda Sobeski Farho, PharmD, BCPS Assistant Professor, Pharmacy Practice UNMC College of Pharmacy Critical Issues in Geriatrics June 24, 2010
Pharmacologic Treatment of Depression Linda Sobeski Farho, PharmD, BCPS Assistant Professor, Pharmacy Practice UNMC College of Pharmacy Critical Issues in Geriatrics June 24, 2010 1 Disclosure I have no
More informationTREATMENT OF DEPRESSION IN LATE LIFE. Robert Kohn, MD
TREATMENT OF DEPRESSION IN LATE LIFE Robert Kohn, MD WHY TREAT ELDERLY PERSONS Major depression is not a normal part of aging The rates are lower than younger cohorts The prevalence rates are still high
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Antidepressant Agents Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Antidepressant Agents Prime Therapeutics will review Prior Authorization requests.
More informationAntidepressants Choosing the Right One
Antidepressants Choosing the Right One Dr Lim Boon Leng Consultant Psychiatrist Dr BL Lim Centre For Psychological Wellness #09-09, Gleneagles Medical Centre, 6 Napier Rd, S258499 www.psywellness.com.sg
More informationDepression Pharmacology. PHPP 517 (IT-III) Fall 2011
Depression Pharmacology PHPP 517 (IT-III) Fall 2011 Depression Symptoms of Depression Emotional symptoms Physical symptoms Cognitive symptoms Psychomotor symptoms Depression Pharmacology Loss of brain
More informationRATIONALE FOR INCLUSION IN PA PROGRAM
RATIONALE FOR INCLUSION IN PA PROGRAM Background Methadone hydrochloride is a long-acting opioid agonist at mu-opioid receptors that is used to manage pain that requires long-term, daily opioid treatment
More informationOptimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE
Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationAffective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018
Affective or Mood Disorders Dr. Alia Shatanawi March 12, 2018 Affective or Mood Disorders Reactive Depression. Secondary: Medical Neurological Drugs Major (Endogenous) Depression = Unipolar: Depressed
More informationLevorphanol. Levorphanol Tartrate. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 17, 2017 Levorphanol Description Levorphanol
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Antidepressant Agents Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Antidepressant Agents Prime Therapeutics will review Prior Authorization requests.
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationPSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
More informationAntidepressant Agents Step Therapy and Quantity Limit Program Summary
Antidepressant Agents Step Therapy and Quantity Limit Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-20,26,27,30,32-35,37-39,40,41,43 Drug MDD OCD PD GAD SAD PDD PTSD Bulimia Other Diagnos es Dosing
More informationPsychopharmacological Management of Depressive and Anxiety Disorders
Psychopharmacological Management of Depressive and Anxiety Disorders Waseem Ahmed, M.D Medical Director: Population Health and Dallas County Correctional System Email: waseem.ahmed@phhs.org Tel: 214-653-2927
More informationPrepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.
Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Sources: National Institute of Mental Health (NIMH), the National Alliance on Mental Illness (NAMI), and from the American Psychological Association
More informationDepression. There are several forms of depression (depressive disorders). Major depressive disorder and dysthymic disorder are the most common.
Depression Depression is a state of low mood and aversion to activity that can affect a person's thoughts, behavior, feelings and sense of well-being. People with depressed mood can feel sad, anxious,
More informationButrans (buprenorphine patch) Description. Section: Prescription Drugs Effective Date: October 1, 2017
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Butrans Page: 1 of 9 Last Review Date: September 15, 2017 Butrans (buprenorphine patch) Description
More informationNucynta IR. Nucynta IR (tapentadol immediate-release) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta IR Page: 1 of 9 Last Review Date: December 8, 2017 Nucynta IR Description Nucynta IR (tapentadol
More informationANTI-DEPRESSANT MEDICATIONS
ANTI-DEPRESSANT MEDICATIONS This information is not intended to be a substitute for medical advice. It s purpose is solely informative. If your client or yourself are taking antidepressants, do not change
More informationBelbuca (buprenorphine buccal film) Belbuca (buprenorphine buccal film) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Belbuca Page: 1 of 9 Last Review Date: September 15, 2017 Belbuca (buprenorphine buccal film)
More informationLevorphanol. Levorphanol Tartrate. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 16, 2018 Levorphanol Description Levorphanol
More informationAntidepressant Pharmacology An Overview
Figure 1. Antidepressant Pharmacology An Overview Source: NEJM 2005;353:1819-34 Figure 2. 1 Figure 3: Antidepressant Pharmacology pictures: Weak inhibition Bupropion NOTE: CYP enzymes noted are those inhibited
More informationANTIDEPRESSANTS IN USE IN CLINICAL PRACTICE
Medicinska naklada - Zagreb, Croatia Conference paper ANTIDEPRESSANTS IN USE IN CLINICAL PRACTICE Mark Agius 1 & Hannah Bonnici 2 1 Clare College, University of Cambridge, Cambridge, UK 2 Hospital Pharmacy
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationMajor Depressive Disorder
Major Depressive Disorder HEDIS Measures And Clinical Practice Guidelines Jennifer Highley, PMHNP-BC Behavioral Health West Point Healthcare Effectiveness Data and Information Set (HEDIS) Performance measures
More informationRealities of Depression in Primary Care Setting
Realities of Depression in Primary Care Setting Jaroslava Salman, MD Department of Supportive Care Medicine Division of Psychiatry Click to edit Master Presentation Date August 4 th 2018 Disclosure I have
More informationThe Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?
The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 9 Last Review Date: September 15, 2017 Duragesic patch Description Duragesic patch (fentanyl
More informationDemerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Meperidine Page: 1 of 7 Last Review Date: September 15, 2017 Meperidine Description Demerol (meperidine
More informationDepression & Anxiety in Adolescents
Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with
More informationDaniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School
Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School of Psychology, Fuller Theological Seminary Medical
More informationBelbuca (buprenorphine buccal film) Description. Section: Prescription Drugs Effective Date: October 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Belbuca Page: 1 of 9 Last Review Date: September 15, 2016 Belbuca (buprenorphine buccal film)
More informationGuide to Psychiatric Medications for Children and Adolescents
Guide to Psychiatric Medications for Children and Adolescents by Glenn S. Hirsch, M.D. The following guide includes most of the medications used to treat child and adolescent mental disorders. It lists
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Section: Prescription Drugs Effective Date: April1, 2017 Subject: Duragesic patch Page: 1 of 10 Last Review Date: March
More informationHysingla ER. Hysingla ER (hydrocodone bitartrate) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.38 Subject: Hysingla ER Page: 1 of 9 Last Review Date: September 15, 2017 Hysingla ER Description
More informationEmbeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.39 Subject: Embeda Page: 1 of 8 Last Review Date: September 15, 2017 Embeda Description Embeda (morphine
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.
More informationDepression Update. Disclosure. Outline 1/28/2018. David Justice, MD FAPA Director of Behavioral Health Sumter Family Health Center
Depression Update David Justice, MD FAPA Director of Behavioral Health Sumter Family Health Center Disclosure No significant relationships to disclose Outline Overview of depression Standard treatment
More informationMedications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other BUPROPION HCL WELLBUTRIN, 01653 WELLBUTRIN SR, WELLBUTRIN XL BUPROPION HBR APLENZIN 17050 16996 26198 CITALOPRAM CELEXA 10321 GPID 16344 HYDROBROMIDE DESVENLAFAXINE
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More informationMedications Guide: Public Speaking And Social Anxiety
AnxietyHub.org Dr. Cheryl Mathews Medications Guide: Public Speaking And Social Anxiety Copyright 2016 AnxietyHub Medications Specifically for Public Speaking and Social Anxiety This is not intended to
More informationProfessional Practice Minutes September 7 th, 2016
Professional Practice Minutes September 7 th, 2016 1. Lung Cancer Screening : Fast Facts Number 1 killer of both men and women in the US (The Global Burden of Cancer 2013) More people die from lung cancer
More informationMorphine IR Hydromorphone IR Oxymorphone IR. Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone),
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.33 Subject: Morphine IR Drug Class Page: 1 of 11 Last Review Date: December 8, 2017 Morphine IR Hydromorphone
More informationObjectives. Diagnostic Criteria DSM 5. Before we begin I should tell you that. General Diagnostics for Anxiety Disorders 08/02/2014
Before we begin I should tell you that ANTIDEPRESSANT USE IN ANXIETY, DEPRESSION AND BIPOLAR: HELPFUL OR HARMFUL? Rania Kattura, PharmD, MS, BCPP Clinical Assistant Professor University of Texas at Austin
More informationChange Your Brain, Change Your Life. The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness
Change Your Brain, Change Your Life The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness Daniel G Amen Three Rivers Press New York Appendix Medication 1.
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description. Section: Prescription Drugs Effective Date: January 1, 2019
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Duragesic patch Page: 1 of 9 Last Review Date: November 30, 2018 Duragesic patch Description Duragesic patch (fentanyl
More informationMAJOR DEPRESSION CLINICAL PRACTICE GUIDELINE
MAJOR DEPRESSION CLINICAL PRACTICE GUIDELINE Reviewed and Updated by the Behvioral Health Subcommittee 7/20/2017 Topic Purpose Access Assessment 7/2017 Recommendations SummaCare Health Plan bases its Clinical
More informationTreatment of Depression in the Primary Care Office
Treatment of Depression in the Primary Care Office Paul E.A. Glaser, MD, PhD Departments of Psychiatry, Pediatrics and Anatomy & Neurobiology University of Kentucky November 5, 2010 Disclosures of Potential
More informationDrug Effectiveness Review Project (DERP) Summary Report on Second-Generation Antidepressants and Antidepressants Literature Scan
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationEducational Objectives: Outline. Relevant Disclosures. Managing Depression in Primary Care Lake Tahoe, August 2011
Managing Depression in Primary Care Lake Tahoe, August 2011 Descartes Li, M.D. Clinical Professor University of California, San Francisco descartes.li@ucsf.edu Educational Objectives: By the end of the
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationDepression and Anxiety. What is Depression? What is Depression? By Christopher Okiishi, MD Spring Not just being sad A syndrome of symptoms
Depression and Anxiety By Christopher Okiishi, MD Spring 2016 What is Depression? Not just being sad A syndrome of symptoms Depressed mood Sleep disturbance Decreased interest in usual activities (anhedonia)
More informationRuby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018
Ruby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018 Objectives Describe pharmacology of commonly prescribed drugs for stimulants and hypnotics Brief review of common drugs that affect sleep
More informationDepression: A Darker Shade of Blue. CareOregon Pharmacy
Depression: A Darker Shade of Blue CareOregon Pharmacy Today s Agenda Welcome and Introduction 8:00 Clinical & In Real Life Aspects 8:05 Break 9:15 Medication Review 9:30 Questions 10:30 Closing 10:55
More informationPsychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA
Psychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA Goals of Medications Use least number at lowest dose to get
More informationBefore you try another medication, try asking your DNA
Before you try another medication, try asking your DNA It s not you, it s your genetics If you re having trouble finding a medication that works for you, don t give up hope. Here s the thing we all respond
More informationTarginiq ER (oxycodone/naloxone extended-release), Troxyca ER (oxycodone /naltrexone extended-release)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.44 Subject: Oxycodone Naloxone Page: 1 of 9 Last Review Date: December 2, 2016 Oxycodone Naloxone
More informationManagement of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors*
Management of SSRI Induced Sexual Dysfunction John J. Miller, M.D. Medical Director, Center for Health and WellBeing Exeter, NH Serotonin Reuptake Inhibitors* fluoxetine clomipramine sertraline paroxetine
More informationOxycodone. Oxycodone IR, Oxycodone ER, OxyContin, Xtampza ER. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Oxycodone Page: 1 of 11 Last Review Date: March 17, 2017 Oxycodone Description Oxycodone IR, Oxycodone
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationOxycodone. Oxycodone IR, Oxycodone ER, OxyContin, Xtampza ER. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Oxycodone Page: 1 of 10 Last Review Date: September 15, 2016 Oxycodone Description Oxycodone IR,
More informationDrugs for Emotional and Mood Disorders Chapter 16
Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationSUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816
SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SPA PCP Treatment & Referral Guideline Managing Depression in Older Adults Developed March 1, 2003 Revised September 21,
More informationDrugs Used in Mood Disorders
33 Drugs Used in Mood Disorders Herbert E. Ward and Albert J. Azzaro DRUG LIST GENERIC NAME PAGE GENERIC NAME PAGE Amitriptyline 389 Amoxapine 389 Bupropion 388 Carbamazepine 395 Citalopram 388 Clomipramine
More informationMonoamine oxidase inhibitors (MAOIs) have wellestablished
SECOND OF 2 PARTS A concise guide to monoamine oxidase inhibitors: How to avoid drug Use these strategies to maximize efficacy and minimize adverse effects when prescribing an MAOI Jonathan M. Meyer, MD
More informationUSF Health Psychiatry Clinic. New Patient Questionnaire Adult
USF Health Psychiatry Clinic New Patient Questionnaire Adult Please mail or fax the completed forms to the address/fax number on the bottom of this page. Completed forms must be received five (5) days
More informationSteps for Initiating Electroconvulsive Therapy Treatment
Steps for Initiating Electroconvulsive Therapy Treatment PSYCHIATRISTS CAN REFER PATIENTS FOR ECT TREATMENT AT EL CAMINO HOSPITAL BY CALLING THE ECT NURSE COORDINATOR AT 650-962-5795. Once the referral
More informationBupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL
Bupropion Generic names Available brands Available strengths and formulations Available in generic Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL 75-mg
More informationObjectives: Lifetime prevalence. Neurotransmitters of interest
Kelly Kll M. Rock, DNP, CRNP 11/5/11 Objectives: Identify lifetime prevalence of depressive and anxious disorders. Recognize the social and economic burden of depressive and anxious disorders. Understand
More informationMEDICATION GUIDE PARNATE
MEDICATION GUIDE PARNATE (PAR-nate) (tranylcypromine) tablets What is the most important information I should know about PARNATE? PARNATE can cause serious side effects including: Increase in suicidal
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationAnxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More information